Company Overview
Tenet Healthcare is America’s third-largest investor-owned hospital company, operating 49 acute care hospitals and more than 580 ambulatory surgery centers through its United Surgical Partners International division across 30 states. It is not a name that generates headlines during weeks when Meta, Microsoft, Apple, and Amazon are all reporting. That relative obscurity is precisely what makes last Wednesday’s Q2 2026 earnings report worth discussing now.
Tenet reported consolidated adjusted EBITDA of $1.304 billion, representing 16.3% year-over-year growth, while adjusted diluted EPS surged 52.2% to $6.12, crushing the $4.23 analyst consensus by 44.7%. Revenue of $5.63 billion topped estimates by 3.7%. Management said the quarter exceeded internal expectations as well — a statement that matters because it suggests the outperformance was supported by durable operating trends rather than one-time gains. Full-year adjusted EPS guidance was raised to $20.30–$21.69, up from the prior $16.38–$18.68 range — an increase of approximately $2.00 at the midpoint. Shares surged 17.6% to $234.03 in after-hours trading on July 23, approaching the company’s 52-week high of $247.21. And despite that move, the stock trades at a P/E ratio of just 12.4 with a PEG ratio of 0.14 — placing it on InvestingPro’s Most Undervalued list.
Key Technical and Fundamental Drivers
44.7% EPS Beat → One of the Largest Surprises in Healthcare This Earnings Season
Adjusted EPS of $6.12 crushed the $4.26 estimate by 43.7–44.7%, with revenue of $5.63 billion surpassing the $5.44 billion consensus by 3.5% and marking 6.8% year-over-year growth. Consolidated adjusted EBITDA grew 16.3% year-over-year to $1.304 billion, exceeding the high end of management’s own prior Q2 guidance range. The magnitude of the EPS beat reflects a combination of same-facility revenue growth, higher patient acuity, disciplined expense management, and approximately $140 million in Medicaid supplemental revenues — a diversified set of drivers rather than a single accounting item.
$295 Million Guidance Raise → Full-Year EBITDA Now $4.83–$5.03 Billion
Tenet raised its full-year 2026 adjusted EBITDA guidance to $4.83–$5.03 billion, a midpoint increase of $295 million, or roughly 6% above the prior range. Full-year adjusted EPS guidance was raised to $20.30–$21.69 from $16.38–$18.68, and adjusted free cash flow guidance was lifted to $1.825–$2.055 billion, a midpoint increase of $225 million. The guidance raise reflects roughly $100 million of first-half fundamental outperformance plus an expected additional $60 million in the second half, meaning the raise is grounded in business momentum rather than one-time items or accounting adjustments.
$1 Billion in Q2 Share Buybacks → $2.13 Billion Authorization Remaining
Tenet repurchased 5.68 million shares for $1.042 billion in Q2 2026 alone, and the board increased the repurchase authorization by $2.0 billion, leaving $2.13 billion available for future buybacks. A company buying back $1 billion of stock in a single quarter — at a P/E of 12.4 — is making an extremely direct statement about where management believes intrinsic value sits relative to the current share price. The $2.13 billion remaining authorization, against a market cap of approximately $19 billion, represents meaningful structural support for the stock over the next several quarters.
USPI Ambulatory Surgery Centers → The High-Margin Growth Engine
United Surgical Partners International adjusted EBITDA guidance was raised to $2.16–$2.22 billion for the full year, with hospital adjusted EBITDA guidance lifted to $2.67–$2.81 billion — a midpoint increase of $285 million. USPI’s ambulatory surgery centers are the highest-margin assets in Tenet’s portfolio — outpatient surgical procedures typically carry better reimbursement rates, lower costs, and higher patient satisfaction than inpatient hospital stays. The shift of surgical volume from hospital settings to ambulatory centers is a structural trend in U.S. healthcare that Tenet is specifically positioned to capture through USPI’s 580+ facility network.
12.4x P/E, 0.14 PEG → Cheapest Quality Healthcare Operator in the Market
The stock trades at a P/E ratio of just 12.4 with a PEG ratio of 0.14, suggesting the shares remain undervalued despite the 17.6% post-earnings surge. A PEG ratio of 0.14 — where anything below 1.0 is conventionally considered undervalued — implies the market is pricing Tenet’s earnings growth at a fraction of what the growth rate would normally justify. For context, the S&P 500 trades at roughly 20x forward earnings with a PEG above 1.5. Tenet, growing EPS 52% year-over-year with a guidance range implying continued acceleration, trades at 12.4x. That divergence is either a structural oversight or a reflection of regulatory risk that the market is pricing more heavily than the current business trajectory warrants.
Market Takeaway
Tenet Healthcare’s Q2 print last Wednesday is the kind of earnings report that gets buried in weeks when four Magnificent Seven companies are reporting simultaneously. A 44.7% EPS beat, 52% EPS growth, $295 million guidance raise, $1 billion in share repurchases, and a stock trading at 12.4x earnings — this is precisely the setup that goes unnoticed when the financial media’s attention is entirely consumed by Meta’s capex guidance and Microsoft’s Azure growth rate.
The longer-term thesis is grounded in one of the most durable trends in American healthcare: the structural shift of surgical volume from expensive inpatient hospital stays to lower-cost, higher-margin ambulatory surgery centers. USPI’s 580+ ASC network is the physical infrastructure capturing that shift, and the double-digit EBITDA growth in that segment is the financial evidence that it’s working. The honest risks deserve direct treatment. The primary payer mix challenge is a significant decline in exchange enrollment and revenues — a direct consequence of ACA subsidy changes that also created headwinds for Intuitive Surgical’s U.S. procedure volumes this quarter. That headwind is real, policy-driven, and uncertain in its duration. Regulatory and reimbursement uncertainty — particularly around Medicaid supplemental programs that contributed $140 million to the guidance raise — introduces variability that makes the full-year guidance range wider than it might otherwise be. And the stock’s $826 million in Q2 net income against $1.042 billion in buybacks means the company is returning more than its GAAP net income to shareholders in a single quarter — an aggressive capital allocation pace that requires sustained free cash flow to maintain. For readers watching Thursday’s session as Apple and Amazon results land alongside the Fed’s rate decision, Tenet Healthcare offers the kind of story that the week’s biggest prints make easy to overlook: a fundamentally improving healthcare business buying back stock aggressively, trading at one of the lowest valuations in its peer group, with a guidance raise that management described as driven by durable operating trends rather than one-time items.